FINTECHTV Editorial Team
Join us for a discussion about how BigHat Biosciences is designing faster and more effective antibody therapies using machine learning and synthetic biology. Our guest, Liz Schwarzbach, Chief Business Officer at BigHat, breaks this down for our guest Vince Molinari.
Host
